Secukinumab (Anti‐IL‐17A Therapeutic Antibody) Improves Clinical Outcome for a Mixed Endotype CRS

Secukinumab (Anti‐IL‐17A Therapeutic Antibody) Improves Clinical Outcome for a Mixed Endotype CRS

ABSTRACT We identified two CRSwNP patients who had previously failed treatment with an anti‐IL‐4/IL‐13 antibody (dupilumab). Based on their clinical characteristics and blood cytokine levels, we considered them mixed Type II/Type III cases and treated them with an anti‐IL‐17 antibody (secukinumab)....

Full description

Saved in:

Bibliographic Details
Main Authors:	Mihkel Plaas, Agnieska Brazovskaja, Kai Kisand, Liina Tserel, Pärt Peterson
Format:	Article
Language:	English
Published:	Wiley 2024-12-01
Series:	Clinical Case Reports
Subjects:	biological treatment biologics chronic rhinosinusitis with polyps CRSwNP dupilumab secukinumab
Online Access:	https://doi.org/10.1002/ccr3.9692
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Investigation of Blood Count-Based Inflammatory Biomarkers as Predictors of Response to Dupilumab Treatment in Patients with Chronic Rhinosinusitis with Nasal Polyps
by: Michael Habenbacher, et al.
Published: (2024-10-01)

Olfactory impairment in Italian patients with chronic rhinosinusitis with nasal polyps: a patient-centered survey
by: Francesca Anastasi, et al.
Published: (2025-01-01)

The “real life” efficacy of dupilumab is independent of initial polyp size and concomitant steroids in CRSwNP
by: Nicholas J. Campion, et al.
Published: (2023-09-01)

What is the impact of biological treatment on sleep quality in chronic rhinosinusitis with nasal polyps patients: a retrospective cross-sectional study
by: Danah Althomaly, et al.
Published: (2024-11-01)

Therapeutic Effectiveness of SNOT 22-Based Interdose Interval Adjustment of Dupilumab for Chronic Rhinosinusitis With Nasal Polyps
by: So Yeon Yoon, et al.
Published: (2024-11-01)

Canadian real-world study of access and clinical results using dupilumab for chronic rhinosinusitis with polyps
by: Shaun J. Kilty, et al.
Published: (2022-04-01)

Successful Treatment of Pediatric Generalized Pustular Psoriasis with Secukinumab
by: Yu K, et al.
Published: (2025-01-01)

Effect of dupilumab on otitis media associated with eosinophilic chronic rhinosinusitis
by: Seiichiro Kamimura, et al.
Published: (2025-03-01)

Persistence of secukinumab in patients with psoriasis, psoriatic arthritis, and ankylosing spondylitis
by: Elena Conesa-Nicolás, et al.
Published: (2021-01-01)

Update on the Biological and Clinical Relevance of Mast Cells in Chronic Rhinosinusitis with Nasal Polyps
by: Luca Giovanni Locatello, et al.
Published: (2024-11-01)

Lack of reactivation of tuberculosis in patients with psoriasis treated with secukinumab in a real-world setting of latent tuberculosis infection
by: Matteo Megna, et al.
Published: (2022-07-01)

ADGRB3-High and POSTN-High Fibroblasts Are Markers of Endotypic Traits in Chronic Rhinosinusitis
by: Hideyuki Takahashi, et al.
Published: (2024-12-01)

Real-World Evaluation of Dupilumab in the Long-Term Management of Eosinophilic Chronic Rhinosinusitis with Nasal Polyps: A Focus on IL-4 and IL-13 Receptor Blockade
by: Nicola Lombardo, et al.
Published: (2024-12-01)

Long-term effects of dupilumab on chronic rhinosinusitis with nasal polyps: A step towards clinical remission
by: Mona Al-Ahmad, MD, FRCPC, et al.
Published: (2025-02-01)

Personalized Secukinumab Treatment in Patients with Plaque Psoriasis Using Model-Informed Precision Dosing
by: Karine Rodriguez-Fernandez, et al.
Published: (2024-12-01)

A case report of bullous pemphigoid following secukinumab therapy for a patient with psoriasis
by: Guanghan Wang, et al.
Published: (2024-12-01)

The influence of the sinonasal microbiome on the development and management of rhinosinusitis
by: Miriam Lang, et al.
Published: (2025-01-01)

Dupilumab reduces patient-reported cough and improves quality of life in patients with severe eosinophilic asthma with or without chronic rhinosinusitis with nasal polyps: a real-life prospective study
by: Carlo Lombardi, et al.
Published: (2025-08-01)

Secukinumab Treatment in Patients With Hidradenitis Suppurativa in Real-World Clinical Settings: A Multicenter Study
by: Ece Erbağcı, et al.
Published: (2025-01-01)

Effectiveness of dupilumab treatment against refractory eosinophilic chronic rhinosinusitis
by: Daiki Nakashima, MD, et al.
Published: (2025-05-01)

Erythema nodosum followed by eosinophilic pneumonia as an adverse effect of dupilumab treatment in a patient with severe asthma
by: Agnieszka Gawlewicz-Mroczka, et al.
Published: (2024-01-01)

Secukinumab: A safe option to treat psoriasis and psoriatic arthritis in the presence of interstitial lung disease
by: Raja Natarajan
Published: (2019-01-01)

Real-world clinical experience with secukinumab in psoriatic arthritis: an observational study and a literature review
by: Eleonora Celletti, et al.
Published: (2025-01-01)

Bibliometric analysis and description of research trends in the treatment of psoriasis with biologic agents in the past two decades (2004–2023)
by: Yingdong Wang, et al.
Published: (2024-12-01)

Risankizumab Versus Secukinumab: A Real-World Efficacy and Cost per Responder Comparison in Patients With Psoriasis in Italy
by: Federico Pirro, et al.
Published: (2025-01-01)

Real-world efficacy and safety of dupilumab in children with atopic dermatitis under 6 years of age: a retrospective multicentric study
by: Filip Rob, et al.
Published: (2025-12-01)

Granulomatous hyperinflammatory state induced by dupilumab treatment for eosinophilic esophagitis
by: Kanak V. Kennedy, MD, et al.
Published: (2024-11-01)

Effectiveness and safety of secukinumab in axial spondyloarthritis and psoriatic arthritis: A retrospective analysis of its real-world usage from India
by: Sham Santhanam, et al.
Published: (2020-01-01)

Clinical features, treatment, and prognosis of secukinumab-induced inflammatory bowel disease
by: Ronghui Li, et al.
Published: (2025-01-01)

Canadian Rhinology Working Group consensus statement: biologic therapies for chronic rhinosinusitis
by: Andrew Thamboo, et al.
Published: (2021-03-01)

Evaluation of serum levels of Interleukin -1 and Tumor Necrosis Alpha (TNF-α) and their nucleotide polymorphisms in patients with chronic rhinosinusitis.
by: Abdelhakim Fouad Ghallab, et al.
Published: (2024-11-01)

Predicting the effectiveness of omalizumab in patients with refractory chronic rhinosinusitis with nasal polyps comorbid with asthma based on inflammatory biomarkers
by: Yutong Sima, MD, et al.
Published: (2025-01-01)

Real-Life Data of Secukinumab in Patients with Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis, and Ankylosing Spondylitis: Patient Baseline Characteristics Data from the PROMPT Study
by: Ploysyne Rattanakaemakorn, et al.
Published: (2024-11-01)

Neutrophil extracellular traps as an important part of the pathogenesis of chronic rhinosinusitis without polyps
by: Valery М. Svistushkin, et al.
Published: (2024-10-01)

Superior effect of adalimumab versus secukinumab on ultrasound-confirmed synovitis in psoriatic arthritis: comprehensive evidence from musculoskeletal ultrasound and clinical assessments
by: Yiyi Wang, et al.
Published: (2024-12-01)

Fractional Carbon Dioxide Laser Combined with Secukinumab in the Treatment of Refractory Psoriasis Lesions on the Lower Legs
by: Ye H, et al.
Published: (2024-12-01)

Cross-border collaboration, communication, and research frontiers on biologics in chronic rhinosinusitis from 2004 to 2023
by: Guan-Jiang Huang, et al.
Published: (2024-12-01)

Long-Term efficacy and safety analysis of secukinumab in the treatment of pediatric generalized pustular psoriasis: a real-world study
by: Lu Xing, et al.
Published: (2025-12-01)

Recurrent NTM pulmonary disease despite avoidance of hot spring exposure in a plaque psoriasis patient treated with Secukinumab: a case report
by: Yixiao Wei, et al.
Published: (2025-01-01)

Anti–IL-4Ra therapy is superior to other biologic classes in treating allergic bronchopulmonary aspergillosis
by: Pedro A. Lamothe, MD, PhD, et al.
Published: (2025-02-01)